Streetbeat News

Revenues

PRVA

In the last three months, 8 analysts have rated Privia Health Gr (NASDAQ:PRVA), with recent ratings showing a mix of bullish to indifferent sentiments. The average 12-month price target has been adjusted to $27.25, down from $32.14, reflecting a 15.21% decline. Analysts from firms like Canaccord Genuity, JP Morgan, and Barclays have adjusted their ratings and price targets, indicating a varied outlook on the company's future performance. Privia Health Gr has shown notable revenue growth of 20.97% as of December 31, 2023, and outperforms industry averages in net margin, ROE, and ROA, with a very low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 3:01 pm

AAP

Advance Auto Parts (NYSE:AAP) has received neutral ratings from analysts, with a consensus price target of $68, marking a significant increase from the previous target of $52.75. Despite facing revenue challenges with a slight decline, the company's financial performance remains strong, with notable net margin, ROE, and ROA figures. Analysts have adjusted their price targets and ratings based on recent market conditions and company performance, reflecting a cautiously optimistic outlook for AAP.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 3:01 pm

KMX

Analysts have mixed views on CarMax (NYSE:KMX), with recent ratings showing a shift towards a more cautious stance. The average 12-month price target is $78.00, indicating a 19.39% increase from the previous target. CarMax's financial performance shows a decline in revenue growth but strong profitability metrics. The company is the largest used-vehicle retailer in the U.S., aiming for over 5% market share by 2025.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 3:00 pm

PANW

Analysts have mixed views on Palo Alto Networks (NASDAQ:PANW), with recent ratings ranging from bullish to indifferent. The average 12-month price target is $352.03, up from $345.56, with high and low estimates of $450.00 and $265.00, respectively. Analyst actions include both upgrades and downgrades, reflecting dynamic market conditions and company performance. Palo Alto Networks, a cybersecurity vendor, has shown strong financial performance with a revenue growth rate of 19.33%, a net margin of 88.45%, an ROE of 53.52%, and an ROA of 10.56%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 3:00 pm

AYRWF

CRLBF

GTBIF

MRMD

TCNNF

The cannabis industry is experiencing significant growth with new store openings and sales milestones ahead of the Benzinga Cannabis Capital Conference in Florida. Illinois' cannabis market continues to expand, with MariMed Inc. opening a new Thrive dispensary. In Florida, Trulieve Cannabis Corp. and Green Thumb Industries Inc. are expanding their retail footprints amid talks of recreational legalization. AYR Wellness Inc. relocated its Tallahassee dispensary, and in New Jersey, C3 Industries Inc. and Holistic Re-Leaf opened new stores. Pennsylvania sees expansion with new dispensaries by PharmaCann Inc. and Cresco Labs Inc.

Portfolio Pulse from Jelena Martinovic

March 19, 2024 | 2:51 pm

CVX

UGA

USO

XLE

XOM

Gas prices are rising, with the national average at $3.49 and some West Coast states over $4. The surge is attributed to drone attacks on Russian refineries by Ukraine, affecting up to 15% of Russia's refining capacity. This has led to higher wholesale gasoline prices, with the United States Gasoline Fund (UGA) reaching its highest level since September. Crude oil prices are also near four-month highs, impacting U.S. inflation and delaying expected Federal Reserve rate cuts. Exxon Mobil Corp (XOM) and Chevron Corp (CVX) stocks have risen due to the strength in oil prices, as has the Energy Select Sector SPDR Fund (XLE), which tracks U.S. oil companies.

Portfolio Pulse from Neil Dennis

March 19, 2024 | 2:48 pm

COSM

Cosmos Health Inc. (NASDAQ:COSM) is nearing regulatory approval in the UK for its C-Scrub disinfectant hand soap and has received its first purchase order. The approval from the UK's Health Security Agency will enable distribution across the UK, with plans to supply the National Health Service. C-Scrub is a biocide disinfectant formulated with 4% chlorhexidine gluconate, offering up to 6 hours of antimicrobial action. Cosmos Health is also exploring opportunities in non-EU markets, targeting the global hospital disinfectant market projected to reach $75.6 billion by 2033.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 2:13 pm

CTRN

Citi Trends Inc (NASDAQ:CTRN) reported Q4 FY23 sales of $215.18 million, missing estimates and showing a 1.5% decline in comparable store sales. Adjusted EPS was $0.53, below the expected $0.80, with a gross margin decrease and a 23.3% inventory increase. Despite this, the company has a positive outlook for FY24, planning new stores, remodels, and closures for optimization. Shares fell 7.46% to $28.40.

Portfolio Pulse from Shivani Kumaresan

March 19, 2024 | 2:04 pm

TASK

Analysts have mixed views on TaskUs (NASDAQ:TASK), with ratings ranging from bullish to bearish over the last quarter. The average 12-month price target has increased to $14.25, up 6.9% from $13.33. Recent analyst actions include ratings and price target adjustments by Guggenheim, RBC Capital, B of A Securities, and Citigroup. TaskUs's financials show a decline in revenue growth, but strong net margin, ROE, and ROA, with a debt-to-equity ratio below industry norms.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 2:01 pm

ALPN

Six financial analysts have recently provided ratings on Alpine Immune Sciences (NASDAQ:ALPN), with a mix of bullish and somewhat bullish perspectives. The average 12-month price target for ALPN is now $41.5, marking a significant increase from the previous average of $27.40. This adjustment reflects a positive sentiment shift among analysts, with recent actions including rating upgrades and price target raises by firms such as Wedbush, Oppenheimer, HC Wainwright & Co., and RBC Capital. Alpine Immune Sciences, a clinical-stage biopharmaceutical company, has shown a revenue growth rate of 20.03% as of September 30, 2023, but faces challenges in net margin, ROE, and ROA, despite a strong market capitalization and sound debt management.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 2:01 pm